Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

455
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
455
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

848
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
848
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

781
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
781
Common Respiratory Disorders01:31

Common Respiratory Disorders

1.3K
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

786
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
786

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Funding for School Based Health Care Mental Health Services is Essential for Latino Youth.

Journal of health care for the poor and underserved·2026
Same author

Rotavirus Vaccines Are Safe and Effective: So Why Aren't All Children Protected?

Pediatrics·2026
Same author

Influence of Community-Level Factors on Health Care Provider Recommendations for HPV Vaccine.

Pediatrics open science·2026
Same author

Childhood Vaccine Hesitancy.

The New England journal of medicine·2026
Same author

Penicillin allergy removal on history alone: delabeling outcomes in a pediatric cohort.

The journal of allergy and clinical immunology. In practice·2026
Same author

Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years.

Pediatrics·2026

相关实验视频

Updated: Jan 15, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

临床进展说明:呼吸道同胞性病毒

Justin B Searns1,2, Sean T O'Leary2

  • 1Department of Pediatrics, Section of Hospital Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

Journal of hospital medicine
|October 13, 2025
PubMed
概括

新的呼吸道同胞病毒 (RSV) 免疫提供了希望,可能防止全球数百万住院和死亡. 本审查审查了这些重要新疫苗的证据和影响.

科学领域:

  • 免疫学 免疫学 免疫学
  • 公共卫生 公共卫生
  • 传染性疾病 传染性疾病

背景情况:

  • 呼吸道同胞体病毒 (RSV) 导致全球显著的发病率和死亡率,每年有超过360万例住院治疗和10万例死亡.
  • 目前对RSV的预防策略有限,这突显了对有效干预的迫切需要.

研究的目的:

  • 审查证据支持最近批准的呼吸道同胞病毒 (RSV) 免疫接种.
  • 检查这些新的RSV免疫策略在减少住院治疗和死亡率方面的潜在公共卫生影响.
  • 评估这些疫苗在减轻RSV全球负担方面的作用.

主要方法:

  • 对临床试验数据和新RSV免疫接种的流行病学研究的文献综述.
  • 分析与RSV疫苗接种相关的医疗保健成本效益和死亡率降低.
  • 对每种已批准的免疫接种的目标患者群体的检查.

主要成果:

  • 自2023年以来,已经批准了三种不同的RSV免疫,每种针对特定患者群体量身定制.
  • 这些免疫有很大的潜力,可以预防与RSV相关的住院治疗.
  • 预计这些疫苗的实施将降低医疗保健系统的成本并挽救生命.

结论:

更多相关视频

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K

相关实验视频

Last Updated: Jan 15, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K
  • 新批准的RSV免疫接种是预防严重呼吸道疾病的重大进展.
  • 这些疫苗有望显著降低全球呼吸道同胞病毒的负担.
  • 进一步的研究和实施策略至关重要,以最大限度地提高RSV疫苗接种对公共卫生的益处.